TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Different Stimulation Patterns to Reduce Muscle Fatigue During FES

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* incomplete spinal cord injury~* able to give informed consent~* able to sit up in a chair~Exclusion Criteria:~* female subjects who are pregnant~* significant history of autonomic dysreflexia~* unable to give informed consent~* individuals who have a cardiac history~* individuals who have significant cognitive impairment~* individuals with muscular abnormality~* individuals who have significant contractures in the lower extremities~* individuals who have a rash or infection at the site of electrode placement (gastrocnemius for both legs)~* individuals who are hypersensitive to electrical stimulation~* individuals who are presently involved in another study which has overlap with the methodology and/or outcomes of the studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: CSS & AsynS (Type: EXPERIMENTAL): Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Sequential Stimulation (ASynS) - CSS/ASynS
- Group B: CSS & AsynR (Type: EXPERIMENTAL): Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Random Stimulation (ASynR) - CSS/ASynR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tailored Treatment in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Metastatic colorectal cancer~* Histopathological verification of the primary tumor~* Measurable disease according to RESIST criteria~* Single agent chemotherapy indicated~* Performance status \>=2~* Age \>= 60 years~* Life expectancy \> 3 months~* Adequate liver and kidney function as evaluated by bilirubin \<= 3 times of normal upper limit, ALAT \<= 3 times upper normal limit (\<= 5 times upper normal limit in case of liver metastases), serum creatinine \<= 1.5 times normal upper limit.~* ANC \>=1.5 x 109/l and platelets \>= 100 x 109/l~* Informed consent~Exclusion Criteria:~* Patients with CNS metastases~* Other malignant disease within the last 5 years except for non-melanoma skin cancer and carcinoma in situ of cervix uteri~* Previous chemotherapy for metastatic disease~* Adjuvant chemotherapy \< 6 months before inclusion~* Patients with previous major toxic or allergic reaction to the protocol drugs

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed renal cell carcinoma~  * Locally advanced unresectable or metastatic disease~* Unidimensionally measurable disease by physical exam or imaging study~  * The following are not considered measurable disease:~    * Bone only disease~   * Pleural or peritoneal effusions~   * CNS lesions~   * Irradiated lesions unless disease progression was documented after radiotherapy~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* ALT and AST \< 3 times upper limit of normal~* Bilirubin ≤ 2.0 mg/dL~Renal~* Creatinine ≤ 2.0 mg/dL~Gastrointestinal~* No active inflammatory bowel disease~* No significant bowel obstruction~* No chronic diarrhea~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after study participation~* No mental incapacitation or psychiatric illness that would preclude giving informed consent~* No other active malignancy except nonmelanoma skin cancer~* No other severe disease that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 4 weeks since prior immunotherapy~* No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)~Chemotherapy~* No prior chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent hormones except steroids for adrenal failure, hormones for non-disease-related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic~Radiotherapy~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy~* No concurrent palliative radiotherapy~Surgery~* Not specified~Other~* No concurrent participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Irinotecan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histological or radiological evidence of stage I or II pancreatic cancer No evidence of metastatic disease on CT scan~PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No prohibitive anesthetic risk due to cardiac disease Pulmonary: No prohibitive anesthetic risk due to respiratory disease~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: No adhesions from previous surgery that preclude laparoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years, \< 70 years, inclusive~* Type 2 diabetes on stable doses of sulfonylurea and/or metformin~* Body mass index \> 35 kg/m2~* Presumed diagnosis of NAFLD based upon~* an ALT \> 1.5 times the upper limit of reference range,~* no evidence of other causes of liver disease and~* ultrasound findings compatible with fatty liver~Exclusion Criteria:~* Clinical signs of cirrhosis as evidenced by any of the following~* spider angiomata,~* splenomegaly,~* ascites~* jaundice~* encephalopathy~* INR \> 1.2~* Platelet count \< 100,000/ml~* Serum albumin \< 3.0 g/dL~* Other liver disease including chronic viral hepatitis (B or C), alcohol abuse, hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, Wilson's disease, primary sclerosing cholangitis or primary biliary cirrhosis.~* Current use of \> 20 g of alcohol per day or unwillingness to avoid alcohol during the course of the study~* Treatment with a thiazolidinedione or exenatide within 6 months of enrolling in the study~* AST or ALT \> 10 times the upper limit of normal~* Treatment with any investigational drug within 4 weeks of enrollment~* Pre-menopausal, fertile women unwilling to use contraceptives during the study period.~* Pregnancy or lactation~* Initiation or change in dose of hypolipidemic drugs (statins, niacin, cholestyramine are allowed) within 6 months of enrollment~* Use of anticoagulation, bleeding disorders or other contraindications to liver biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant patients with a previous history of preeclampsia in the immediate preceding pregnancy.~* 18 to 45 years of age will be included.~Exclusion Criteria:~* Patients with chronic hypertension~* children (age \< 17 years)~* Patients that are currently taking anti-psychotics or Selective Serotonin Re-uptake Inhibitors~* patients on medications which may be detrimental to the study interpretation will also be excluded at the principal investigator's discretion.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin plus Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Drug: Aspirin 81 mg, given orally once per day Drug: Placebo tablet given orally, once a day
- Aspirin plus Progesterone (Type: ACTIVE_COMPARATOR): Drug: Aspirin 81mg, given orally once per day Drug: Progesterone 200mg given orally, once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Different Up-dosing Schedules With Osiris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* history of grass pollen allergy~* Positive SPT to grass~* Positive IgE to grass~Exclusion Criteria:~* uncontrolled and severe asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OSIRIS (Type: ACTIVE_COMPARATOR): None
- OSIRIS other concentration 1 (Type: EXPERIMENTAL): None
- OSIRIS other concentration 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects 55 to 80 years with histologically or cytologically documented primary intraductal or lobular invasive breast cancer that meets the following criteria:~* T2, N0 or N1, M0.~* Primary tumour clinically determined to be 2 to 5 cm in the greatest dimension.~* Laboratory documentation of positive oestrogen receptor (ER+) status in at least 10% of the tumour cells.~* Laboratory documentation of HER-2 negative status.~Postmenopausal defined as~* no spontaneous menses for a total of 2 years~* amenorrheic for at least 12 months with serum oestrogen level \<30 pg/mL, and both luteinising hormone (LH)/follicle stimulating hormone (FSH) \>20 IU/L, chemotherapy-induced amenorrhoea for at least 12 months~* bilateral oophorectomy, or radiation castration and amenorrhoeic for at least 3 months.~Eastern Cooperative Oncology Group (ECOG) performance status ≤2.~Exclusion Criteria:~* Has locally advanced breast cancer that is considered non-operable without neoadjuvant therapy.~* Has evidence of metastatic disease~* as a diagnosis of inflammatory breast cancer~* Has ductal carcinoma in situ

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BN83495 (Type: EXPERIMENTAL): 40mg tablet oral daily administration from Day 1 to Day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tobacco's Impact on Postoperative Complications in Acute Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute admittance in a vascular department~* current smoker~* surgery within 7 days~* informed/written consent~Exclusion Criteria:~* alcohol intake \> 35 units pr. week~* dementia or mental disease~* \> 90 years

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Smoking intervention, Nicotine replacement therapy. (Type: ACTIVE_COMPARATOR): None
- Controlgroup (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post-menopausal women~* Aromatase inhibitor as the last hormonal treatment~* Breast adenocarcinoma with positive hormone receptor~* Measurable disease as per RECIST definition~Exclusion Criteria:~* ECOG performance status (PS) \> 2~* Prior exposure to fulvestrant or to an anti IGF-1R compound~* No evidence of hormonosensitivity~* HER 2-neu positive tumor~* More than one prior regimen of chemotherapy for metastatic disease~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with stable chronic coronary artery disease scheduled for elective percutaneous intervention.~Exclusion Criteria:~* Recent (1 month) myocardial infarction~* Acute coronary syndrome~* Chest pain at res~* Estimated glomerular filtration rate(GFR)\<45 mL/min/1.73 m2~* Frequent premature atrial or ventricular contractions or atrial fibrillation~* Any contraindication to MRI including implanted non MRI compatible medical devices or ferromagnetic materials such as shrapnel~* Inability to breath-hold~* Severe claustrophobia~* Deafness~* Persistent tremor~* Inability to follow instructions.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Remote Ischemic Preconditioning (RIPC) (Type: EXPERIMENTAL): Randomized subjects who are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
- Sham Remote Ischemic Preconditioning (Type: PLACEBO_COMPARATOR): Patients who prior to stenting have the RIPC blood pressure cuff placed but not inflated for 3 5 minute episodes with 5 minute rest periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Maternal age ≥ 18 years~* Preterm premature rupture of membranes, demonstrated clinically by speculum exam~* Cervical dilation visually ≤ 5cm on sterile speculum exam~* Planned delivery at John Sealy Hospital (JSH)~* Gestational age of membrane rupture and initiation of first course of antenatal corticosteroids between 23 5/7 - 32 5/7 weeks~* Planned pregnancy continuation with no indication for delivery for at least 7 days~Exclusion Criteria:~* Maternal age \> 50 years~* Gestational age \< 23 5/7 weeks or \> 32 5/7 weeks~* Known major congenital abnormalities, aneuploidy, or genetic syndrome~* Intrauterine fetal demise~* Any indication for expedited delivery~* Maternal chorioamnionitis~* Known allergy or adverse reaction to corticosteroids

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Betamethasone (Type: EXPERIMENTAL): Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
- Saline Placebo (Type: PLACEBO_COMPARATOR): Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bipolar RFA of Painful Extra-spinal Bone Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1) Multi-metastatic cancer patients with at least one painful lytic bone metastasis~* 2) Target lesion should correspond to a specific radiologic finding~* 3) At least a moderate pain produce by target lesion (4 on a scale of 0 to 10 over the prior 24 hours with or without pain killers intake) assessed during selection evaluation~* 4) Patients 18 years old~* 5) Able to give written consent~* 6) Life expectancy 1 months~* 7) Patient affiliated to the National Health Insurance system~Exclusion Criteria:~1. Radiation therapy on the target tumor terminated \< 3 weeks before treatment~2. Any contra-indication for the procedure as stated by the radiologist in terms of tumor size, proximity to neural/vascular structures making the procedure at unacceptable risk~3. Any contra-indication for the procedure as stated by the radiologist related to patient's condition (e.g. cardiac pacemakers) making the procedure at unacceptable risk~4. Impaired haemostasis~5. Concurrent participation in other experimental studies that could affect endpoints of this study~6. Contraindication to any form of sedation/anaesthesia~7. Signs of local/systemic infection identified before procedure, in accordance with standard care~8. Sclerotic metastases~9. Adults under guardianship~10. Patients under judicial protection~11. Pregnant or breastfeeding woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RFA (Type: EXPERIMENTAL): Single-arm prospective observational study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Distress Tolerance for Benzodiazepine Discontinuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Receiving OAT (methadone or buprenorphine) for at least 2 weeks~* Regular BZD use defined by BZD use 3 or more times per week in past month by self-report and positive urine screen at time of recruitment~* Provides permission to contact current BZD prescriber if being prescribed BZDs~* Speaks English~* Wants to discontinue BZD use~* Capacity to provide informed consent~Exclusion Criteria:~* Pregnant, confirmed by urine pregnancy test~* Cognitive impairment, as indicated by Montreal Cognitive Assessment (MoCA): must score at least 26 on the MoCA with a one-point adjustment for individuals with formal education of 12 years or fewer~* Any past month illicit opioid determined by self-report or urine drug test; illicit defined as non-medical use~* Receiving ongoing psychosocial treatment for BZD use disorder~* Uncontrolled seizure disorder (i.e. seizure in prior 90 days), or past BZD withdrawal seizure~* Current suicidality or homicidality~* Current psychotic symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) (Type: EXPERIMENTAL): This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.
- Relaxation Therapy (Type: ACTIVE_COMPARATOR): The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues